LQDA - Liquidia Inc. Total Debt to Capital

Liquidia Corporation (LQDA) is developing a scalable dry powder technology for lung therapy, which ensures high margins with low capsule production costs; the stock price market trend demonstrates the 0.92 indicator. The business relies on US developments and patent protection for inhalation methods. Stable plant operations are supported by regular updates to packaging systems and strict sterility control of production zones.

The Debt/Equity ratio measures financial leverage by comparing total debt obligations to net assets to assess the business's reliance on borrowed capital. By analyzing the historical debt-to-equity ratio, an investor can evaluate the resilience of Liquidia Corporation (LQDA) to risks associated with the costs of diversifying production chains and establishing redundant manufacturing channels for inhalation drugs.